Free Trial
NASDAQ:IMNN

Imunon (IMNN) Stock Price, News & Analysis

Imunon logo
$1.80 +0.28 (+18.42%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Imunon Stock (NASDAQ:IMNN)

Key Stats

Today's Range
$1.60
$1.89
50-Day Range
$0.40
$2.27
52-Week Range
$0.37
$3.65
Volume
8.34 million shs
Average Volume
3.17 million shs
Market Capitalization
$31.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50
Consensus Rating
Moderate Buy

Company Overview

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

IMNN MarketRank™: 

Imunon scored higher than 37% of companies evaluated by MarketBeat, and ranked 801st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Imunon has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Imunon has only been the subject of 3 research reports in the past 90 days.

  • Read more about Imunon's stock forecast and price target.
  • Earnings Growth

    Earnings for Imunon are expected to grow in the coming year, from ($1.68) to ($1.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Imunon is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Imunon is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Imunon has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Imunon's valuation and earnings.
  • Percentage of Shares Shorted

    6.89% of the float of Imunon has been sold short.
  • Short Interest Ratio / Days to Cover

    Imunon has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Imunon has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Imunon does not currently pay a dividend.

  • Dividend Growth

    Imunon does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.89% of the float of Imunon has been sold short.
  • Short Interest Ratio / Days to Cover

    Imunon has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Imunon has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Imunon has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Imunon this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Imunon insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.00% of the stock of Imunon is held by insiders.

  • Percentage Held by Institutions

    Only 4.47% of the stock of Imunon is held by institutions.

  • Read more about Imunon's insider trading history.
Receive IMNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

IMNN Stock News Headlines

How Trade Wars Are Creating Fresh Opportunities for Investors
Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”
Top Penny Stocks To Follow Now - May 26th
See More Headlines

IMNN Stock Analysis - Frequently Asked Questions

Imunon's stock was trading at $0.95 at the beginning of the year. Since then, IMNN stock has increased by 60.0% and is now trading at $1.52.
View the best growth stocks for 2025 here
.

Imunon, Inc. (NASDAQ:IMNN) posted its earnings results on Monday, May, 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07.
Read the conference call transcript
.

Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO).

Company Calendar

Last Earnings
5/12/2025
Today
5/29/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNN
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.50
High Stock Price Target
$17.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+919.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.51 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$500,000.00
Price / Cash Flow
N/A
Book Value
$1.42 per share
Price / Book
1.07

Miscellaneous

Free Float
13,776,000
Market Cap
$26.66 million
Optionable
Not Optionable
Beta
1.75
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IMNN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners